For women who have breast-conserving surgery, radiation therapy is effective in decreasing mortality and recurrence.12,13 Of the nearly 300 000 women diagnosed with breast cancer annually, about 83% have hormone receptor–positive tumors, which makes them eligible for adjuvant hormone therapy that is associated with increased survival and decreased risk of recurrence.33 Yet prior studies associated Medicaid insurance with lower use of both radiation and hormone therapy compared with other insurance.12,13,18 Using registry data alone, our findings confirmed these reported disparities. The gene discussed is NR4A1; the disease is breast carcinoma.